LVTX — LAVA Therapeutics NV Cashflow Statement
0.000.00%
Last trade - 00:00- $45.77m
- -$3.89m
- $11.98m
Annual cashflow statement for LAVA Therapeutics NV, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
R2020 December 31st | 2021 December 31st | 2022 December 31st | R2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 20-F | 20-F | 20-F | 10-K | 10-K |
| Standards: | IFRS | IFRS | IFRS | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -15.5 | -45.2 | -31.7 | -41.9 | -25.1 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 0.962 | 5.15 | 0.807 | 4.85 | 0.73 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 4.73 | 10.8 | 34.1 | -3.88 | 4.38 |
| Change in Accounts Receivable | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -9.31 | -28.6 | 4.04 | -40.3 | -19.5 |
| Capital Expenditures | -0.502 | -0.764 | -0.587 | -0.731 | -0.023 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 0 | -42.8 | 9.93 | -16.9 | 12.5 |
| Sale of Fixed Assets | |||||
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.502 | -43.5 | 9.35 | -17.6 | 12.5 |
| Financing Cash Flow Items | 22 | 61.8 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 19 | 151 | 0.283 | 0 | -0.569 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 8.48 | 75.1 | 9.46 | -56.1 | -9.22 |